Industry To FDA: Rethink Diabetes Drug CV Safety Requirements

Standards in place under a 2008 guidance should be supplanted with cardiovascular safety requirements tailored to individual drugs, PhRMA and BIO say at a public hearing on interim CV data disclosures.